Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 6/2020

Open Access 01-12-2020 | Liver Transplantation | Guidelines

Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group

Authors: Umberto Cillo, Luciano De Carlis, Massimo Del Gaudio, Paolo De Simone, Stefano Fagiuoli, Francesco Lupo, Giuseppe Tisone, Riccardo Volpes

Published in: Hepatology International | Issue 6/2020

Login to get access

Abstract

It is a well-recognized fact that implementing new guidelines in clinical practice may be difficult; therefore the Italian Society for Organ and Tissue Transplantation (SITO) set out to define practical immunosuppression tools for the management of liver transplantation patients. In 2017, an Italian Working Group of liver transplant experts and hepatologists issued a set of consensus statements along with evidence-based recommendations on the use of everolimus after liver transplantation. This article presents the evidence- and consensus-based algorithms developed within the Italian Working Group, which are aimed towards guiding clinicians in the selection of immunosuppressive regimens for the management of adult liver transplant recipients in real-life practice. The liver transplant recipient population, typically managed in clinical practice, was divided into the following categories: (1) standard patients; (2) critically ill patients; (3) patients with a specific etiology; (4) patients with hepatocellular carcinoma; (5) and patients with de novo malignancies. The algorithms are divided into two parts, according to the time from transplantation (0–3 months and > 3 months) and are discussed here along with relevant supporting literature, when available. Ultimately, it is hoped that the evidence- and consensus-based algorithms developed within the Italian Working Group, and presented here, contribute to simplify, personalize, and optimize immunosuppression of liver transplantation recipients in clinical practice.
Appendix
Available only for authorised users
Literature
1.
Nashan B. mTOR Inhibition and clinical transplantation: liver. Transplantation. 2018;102:S19–S26.PubMedCrossRef
2.
Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2001;72:1934–9.PubMedCrossRef
3.
Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397:530–4.PubMedCrossRef
4.
Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931–40.PubMedCrossRef
5.
6.
Jain A, Marcos A, Reyes J, Mazariagos G, Kashyap R, Eghtesad B, et al. Tacrolimus for primary liver transplantation: 12 to 15 years actual follow-up with safety profile. Transplant Proc. 2005;37:1207–10.PubMedCrossRef
7.
Sharma P, Welch K, Eikstadt R, Marrero JA, Fontana RJ, Lok AS. Renal outcomes after liver transplantation in the model for end-stage liver disease era. Liver Transpl. 2009;15:1142–8.PubMedCrossRef
8.
Pham PT, Pham PC, Wilkinson AH. Management of renal dysfunction in the liver transplant recipient. Curr Opin Organ Transplant. 2009;14:231–9.PubMedCrossRef
9.
10.
De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl. 2009;15:1262–9.PubMedCrossRef
11.
De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012;12:3008–200.PubMedPubMedCentralCrossRef
12.
Saliba F, De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant. 2013;13:1734–45.PubMedCrossRef
13.
Saliba F, Dharancy S, Lorho R, Conti F, Radenne S, Neau-Cransac M, et al. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis. Liver Transpl. 2011;17:905–13.PubMedCrossRef
14.
Sterneck M, Kaiser GM, Heyne N, Richter N, Rauchfuss F, Pascher A, et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant. 2014;14:701–10.PubMedPubMedCentralCrossRef
15.
De Simone P, Fagiuoli S, Cescon M, De Carlis L, Tisone G, Volpes R, et al. Use of everolimus in liver transplantation: recommendations from a working group. Transplantation. 2017;101:239–51.PubMedCrossRef
16.
Fagiuoli S, Burra P, Salizzoni M, Cescon M, De Carlis L, Di Costanzo GG, et al. Renal protection strategies are poorly implemented after liver transplantation: the 12-month results of the Italian national study SURF. Abstract BOS433. Transpl Int. 2017;30(Suppl 2):289.
17.
Cillo U, Burra P, Mazzaferro V, Belli L, Pinna AD, Spada M, et al. A multistep, consensus-based approach to organ allocation in liver transplantation: toward a "Blended Principle Model". Am J Transplant. 2015;15:2552–611.PubMedCrossRef
18.
Fischer L, Saliba F, Kaiser GM, De Carlis L, Metselaar HJ, De Simone P, et al. Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: follow-up results from a randomized, multicenter study. Transplantation. 2015;99:1455–62.PubMedCrossRef
19.
Fischer L, Klempnauer J, Beckebaum S, Metselaar HJ, Neuhaus P, Schemmer P, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation–PROTECT. Am J Transplant. 2012;12:1855–65.PubMedCrossRef
20.
Masetti M, Montalti R, Rompianesi G, Codeluppi M, Gerring R, Romano A, et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant. 2010;10:2252–62.PubMedCrossRef
21.
Abdelmalek MF, Humar A, Stickel F, Andreone P, Pascher A, Barroso E, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant. 2012;12:694–705.PubMedCrossRef
22.
Castroagudin JF, Molina E, Romero R, Otero E, Tome S, Varo E. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl. 2009;15:1792–7.PubMedCrossRef
23.
De Simone P, Precisi A, Petruccelli S, Balzano E, Carrai P, Catalano G, et al. The impact of everolimus on renal function in maintenance liver transplantation. Transplant Proc. 2009;41:1300–2.PubMedCrossRef
24.
Carey EJ, Lai JC, Wang CW, Dasarathy S, Lobach I, Montano-Loza AJ, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transpl. 2017;23:625–33.PubMedPubMedCentralCrossRef
25.
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–156.PubMedCrossRef
26.
Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49:M85–94.PubMedCrossRef
27.
Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31:1539–47.CrossRefPubMed
28.
Drenth JP, Chrispijn M, Nagorney DM, Kamath PS, Torres VE. Medical and surgical treatment options for polycystic liver disease. Hepatology. 2010;52:2223–30.PubMedCrossRef
29.
Gevers TJ, Drenth JP. Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol. 2013;10:101–8.PubMedCrossRef
30.
Pita A, Kaur N, Emamaullee J, Lo M, Nguyen B, Sabour A, et al. Outcomes of liver transplantation in patients on renal replacement therapy: considerations for simultaneous liver kidney transplantation versus safety net. Transplant Direct. 2019;5:e490.PubMedPubMedCentralCrossRef
31.
Sharma P. Liver-kidney: indications, patient selection, and allocation policy. Clin Liver Dis (Hoboken). 2019;13:165–9.CrossRef
32.
Gedaly R, Daily MF, Davenport D, McHugh PP, Koch A, Angulo P, et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg. 2011;146:953–8.PubMedCrossRef
33.
Lim C, Lahat E, Osseis M, Sotirov D, Salloum C, Azoulay D. Liver transplantation for neuroendocrine tumors: what have we learned? Semin Liver Dis. 2018;38:351–6.PubMedCrossRef
34.
Mazzaferro V, Sposito C, Coppa J, Miceli R, Bhoori S, Bongini M, et al. The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors. Am J Transplant. 2016;16:2892–902.PubMedCrossRef
35.
Chotai P, Matsuoka L. Reassessing the role of liver transplantation for patients with metastatic colorectal cancer to the liver. Curr Opin Organ Transplant. 2019;24:118–20.PubMedCrossRef
36.
Hagness M, Foss A, Line PD, Scholz T, Jorgensen PF, Fosby B, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg. 2013;257:800–6.PubMedCrossRef
37.
Dueland S, Syversveen T, Solheim JM, Solberg S, Grut H, Bjornbeth BA, et al. Survival following liver transplantation for patients with nonresectable liver-only colorectal metastases. Ann Surg. 2020;271:212–8.PubMedCrossRef
38.
Goldaracena N, Gorgen A, Sapisochin G. Current status of liver transplantation for cholangiocarcinoma. Liver Transpl. 2018;24:294–303.PubMedCrossRef
39.
Sapisochin G, de Lope CR, Gastaca M, de Urbina JO, Lopez-Andujar R, Palacios F, et al. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study. Ann Surg. 2014;259:944–52.PubMedCrossRef
40.
Zaborowski A, Heneghan HM, Fiore B, Stafford A, Gallagher T, Geoghegan J, et al. Neoadjuvant chemoradiotherapy and liver transplantation for unresectable hilar cholangiocarcinoma: the Irish experience of the Mayo Protocol. Transplantation. 2020;104(10):2097–104.PubMedCrossRef
41.
Heits N, Heinze T, Bernsmeier A, Kerber J, Hauser C, Becker T, et al. Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts. BMC Cancer. 2016;16:322.PubMedPubMedCentralCrossRef
42.
43.
Coquillard C, Berger J, Daily M, Shah M, Mei X, Marti F, et al. Combined liver-kidney transplantation for polycystic liver and kidney disease: analysis from the united network for organ sharing dataset. Liver Int. 2016;36:1018–25.PubMedCrossRef
44.
Lauterio A, De Carlis R, Di Sandro S, Buscemi V, Andorno E, De Carlis L. Delayed kidney transplantation in combined liver-kidney transplantation for polycystic liver and kidney disease. Transpl Int. 2019;32:1336–8.PubMedCrossRef
45.
Rousseau B, Guillemin A, Duvoux C, Neuzillet C, Tlemsani C, Compagnon P, et al. Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma. Int J Cancer. 2019;144:886–96.PubMedCrossRef
46.
Montano-Loza AJ, Hansen BE, Corpechot C, Roccarina D, Thorburn D, Trivedi P, et al. Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival. Gastroenterology. 2019;156(96–107):e101.
47.
Cholongitas E, Mamou C, Rodriguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int. 2014;27:1039–49.PubMedCrossRef
48.
Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology. 2010;51:1237–43.PubMedCrossRef
49.
Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther. 2009;9:247–61.PubMedCrossRef
50.
Geissler EK, Schnitzbauer AA, Zulke C, Lamby PE, Proneth A, Duvoux C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation. 2016;100:116–25.PubMedCrossRef
51.
Yanik EL, Chinnakotla S, Gustafson SK, Snyder JJ, Israni AK, Segev DL, et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma. Liver Transpl. 2016;22:627–34.PubMedPubMedCentralCrossRef
52.
Bhoori S, Toffanin S, Sposito C, Germini A, Pellegrinelli A, Lampis A, et al. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. J Hepatol. 2010;52:771–5.PubMedCrossRef
53.
De Simone P, Crocetti L, Pezzati D, Bargellini I, Ghinolfi D, Carrai P, et al. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc. 2014;46:241–4.PubMedCrossRef
54.
Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, et al. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl. 2012;18:45–52.PubMedCrossRef
55.
Grigg SE, Sarri GL, Gow PJ, Yeomans ND. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2019;49:1260–73.PubMedCrossRef
56.
Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005;80:883–9.PubMedCrossRef
57.
Piselli P, Serraino D, Segoloni GP, Sandrini S, Piredda GB, Scolari MP, et al. Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997–2009. Eur J Cancer. 2013;49:336–44.PubMedCrossRef
58.
Bilbao I, Sapisochin G, Dopazo C, Lazaro JL, Pou L, Castells L, et al. Indications and management of everolimus after liver transplantation. Transplant Proc. 2009;41:2172–6.PubMedCrossRef
59.
Vivarelli M, Dazzi A, Cucchetti A, Gasbarrini A, Zanello M, Di Gioia P, et al. Sirolimus in liver transplant recipients: a large single-center experience. Transplant Proc. 2010;42:2579–84.PubMedCrossRef
60.
Jimenez-Romero C, Manrique A, Marques E, Calvo J, Sesma AG, Cambra F, et al. Switching to sirolimus monotherapy for de novo tumors after liver transplantation. A preliminary experience. Hepatogastroenterology. 2011;58:115–21.PubMed
61.
Charlton M, Levitsky J, Aqel B, O'Grady J, Hemibach J, Rinella M, et al. International liver transplantation society consensus statement on immunosuppression in liver transplant recipients. Transplantation. 2018;102:727–43.PubMedCrossRef
Metadata
Title
Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group
Authors
Umberto Cillo
Luciano De Carlis
Massimo Del Gaudio
Paolo De Simone
Stefano Fagiuoli
Francesco Lupo
Giuseppe Tisone
Riccardo Volpes
Publication date
01-12-2020

Other articles of this Issue 6/2020

Hepatology International 6/2020 Go to the issue

Editorial

HBx mutations emerged during antiviral therapy: a new face of a multifaceted HBV protein?

Guidelines

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

Original Article

HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort

Original Article

Double-blind placebo-controlled randomized trial of N-acetylcysteine infusion following live donor liver transplantation

Review Article

Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis

Original Article

A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits